Old	New	Differences
1	1
2	2
3	3
4	4	Req. No. 9116 Page 1 1
5	5	2
6	6	3
7	7	4
8	8	5
9	9	6
10	10	7
11	11	8
12	12	9
13	13	10
14	14	11
15	15	12
16	16	13
17	17	14
18	18	15
19	19	16
20	20	17
21	21	18
22	22	19
23	23	20
24	24	21
25	25	22
26	26	23
27	27	24
28	28	1
29	29	2
30	30	3
31	31	4
32	32	5
33	33	6
34	34	7
35	35	8
36	36	9
37	37	10
38	38	11
39	39	12
40	40	13
41	41	14
42	42	15
43	43	16
44	44	17
45	45	18
46	46	19
47	47	20
48	48	21
49	49	22
50	50	23
51	51	24
52	52
53	53	STATE OF OKLAHOMA
54	54
55	55	2nd Session of the 59th Legislature (2024)
56	56
57	57	HOUSE BILL 3326 By: Staires
58	58
59	59
60	60
61	61
62	62
63	63	AS INTRODUCED
64	64
65	65	An Act relating to narcotic treatment programs;
66	66	amending 43A O.S. 2021, Section 3 -601, as amended by
67	67	Section 2, Chapter 250, O.S.L. 2023 (43A O.S. Supp.
68	68	2023, Section 3-601), which relates to opioid
69	69	substitution treatment programs and compliance;
70	70	modifying mandatory observance of drug abuse testing;
71	71	and providing an effective date .
72	72
73	73
74	74
75	75
76	76
77	77	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
78	78	SECTION 1. AMENDATORY 43A O.S. 2021, Section 3-601, as
79	79	amended by Section 2, Chapter 250, O.S.L. 2023 (43 A O.S. Supp. 2023,
80	80	Section 3-601), is amended to read as follows:
81	81	Section 3-601. A. Any Class II controlled dangerous substance,
82	82	when used in this state by an opioid sub stitution treatment program
83	83	for persons with a history of op ioid addiction to or physiologic
84	84	dependence on controlled dangerous substances, shall only be u sed:
85	85	1. In treating persons with a history of addiction;
86	86	2. In treating persons with a one-year history of opioid
87	87	addiction to or physiologic dependence on controlled dangerous
88	88
89	89
90	90	Req. No. 9116 Page 2 1
91	91	2
92	92	3
93	93	4
94	94	5
95	95	6
96	96	7
97	97	8
98	98	9
99	99	10
100	100	11
101	101	12
102	102	13
103	103	14
104	104	15
105	105	16
106	106	17
107	107	18
108	108	19
109	109	20
110	110	21
111	111	22
112	112	23
113	113	24
114	114	1
115	115	2
116	116	3
117	117	4
118	118	5
119	119	6
120	120	7
121	121	8
122	122	9
123	123	10
124	124	11
125	125	12
126	126	13
127	127	14
128	128	15
129	129	16
130	130	17
131	131	18
132	132	19
133	133	20
134	134	21
135	135	22
136	136	23
137	137	24
138	138
139	139	substances, as defined by the Code of Federal Regulations, and
140	140	documentation of attempting another type of treatment; or
141	141	3. If clinically appropriate, the program physician may waive
142	142	the requirement of a one-year history of opioid addiction for
143	143	consumers within six (6) months of release from a penal institution,
144	144	for consumers with a pregnancy verified by the program physician, or
145	145	for consumers having previously received treatment for opioid
146	146	addiction and within two (2) years of discharge from that treatment
147	147	episode.
148	148	B. Any conviction for a violation of the provis ions of this
149	149	section or any rules promulgated pursuant to the provisions of this
150	150	section shall be a felony.
151	151	C. For the purposes of this section, "opioid substitution
152	152	treatment program" means a person, private physician , or
153	153	organization that administers or dispenses an opioid drug to a
154	154	narcotic addict for the purposes of detoxification or maintenance
155	155	treatment or provides, when necessary and appropriate, comprehensive
156	156	medical and rehabilitation services. A private physician who
157	157	administers buprenorphine wi th a waiver from the Drug Enforcement
158	158	Administration shall not be considered an opioid substitution
159	159	treatment program.
160	160	D. An opioid substitution treatment program shall be certified
161	161	by the Board of Mental Health and Subst ance Abuse Services, or the
162	162	Commissioner of Mental Health and Substance Abuse Services upon
163	163
164	164
165	165	Req. No. 9116 Page 3 1
166	166	2
167	167	3
168	168	4
169	169	5
170	170	6
171	171	7
172	172	8
173	173	9
174	174	10
175	175	11
176	176	12
177	177	13
178	178	14
179	179	15
180	180	16
181	181	17
182	182	18
183	183	19
184	184	20
185	185	21
186	186	22
187	187	23
188	188	24
189	189	1
190	190	2
191	191	3
192	192	4
193	193	5
194	194	6
195	195	7
196	196	8
197	197	9
198	198	10
199	199	11
200	200	12
201	201	13
202	202	14
203	203	15
204	204	16
205	205	17
206	206	18
207	207	19
208	208	20
209	209	21
210	210	22
211	211	23
212	212	24
213	213
214	214	delegation by the Board, and registered with the federal Drug
215	215	Enforcement Administration for the use of an opioid d rug to treat
216	216	narcotic addiction.
217	217	E. The Board of Mental Health and Substance Abuse Se rvices
218	218	shall promulgate rules and standards for the certification of all
219	219	programs, private facilities, and organi zations which provide opioid
220	220	substitution treatment dire cted to those physiologically dependent
221	221	on or addicted to opioids. These facilities and organizations shall
222	222	be known as "Opioid Substitution Treatment Programs". Only
223	223	certified facilities may receiv e and assist opioid-dependent and
224	224	addicted persons by pr oviding Class II controlled substances in
225	225	opioid substitution treatment and rehabilitat ion.
226	226	F. The Board of Mental Health and Substance Abuse Services
227	227	shall promulgate rules and standards regulati ng the treatment and
228	228	services provided by opioid substitut ion treatment programs.
229	229	Failure to comply with rul es and standards promulgated by the B oard
230	230	shall be grounds for revocation, suspension or nonrenewal of
231	231	certification.
232	232	G. An opioid substitution treatment program shall comply with
233	233	all federal requirements for opioid treatment programs provided by
234	234	42 C.F.R., Subpart C including but not limited to t he requirement to
235	235	provide drug abuse testing services provided by 42 C.F.R., Section
236	236	8.12(f)(6). Drug abuse testing shall may be directly observed by an
237	237	employee or contractor of the opioid substitution treatment program.
238	238
239	239
240	240	Req. No. 9116 Page 4 1
241	241	2
242	242	3
243	243	4
244	244	5
245	245	6
246	246	7
247	247	8
248	248	9
249	249	10
250	250	11
251	251	12
252	252	13
253	253	14
254	254	15
255	255	16
256	256	17
257	257	18
258	258	19
259	259	20
260	260	21
261	261	22
262	262	23
263	263	24
264	264	1
265	265	2
266	266	3
267	267	4
268	268	5
269	269	6
270	270	7
271	271	8
272	272	9
273	273	10
274	274	11
275	275	12
276	276	13
277	277	14
278	278	15
279	279	16
280	280	17
281	281	18
282	282	19
283	283	20
284	284	21
285	285	22
286	286	23
287	287	24
288	288
289	289	H. Opioid substitution treatment pro grams shall notify the
290	290	Department of Mental Health and Substance Abuse Services of plans to
291	291	close or relocate within a mi nimum of thirty (30) days prior to
292	292	closure or relocation.
293	293	I. Failure to comply with rules and standards promulgated by
294	294	the Board of Mental Health and Substance Abuse Services pursuant to
295	295	this section or failure to comply with the requirements of 42
296	296	C.F.R., Subpart C shall be grounds for reprimand, suspension,
297	297	revocation or nonrenewal of certification.
298	298	SECTION 2. This act shall become effective November 1, 2024.
299	299
300	300	59-2-9116 TJ 01/15/23

Oklahoma 2024 Regular Session

Oklahoma House Bill HB3326 Compare Versions